Sierra Leone

DEVEX byAlison  Campbell                                                                          April 23, 2015

The Ebola crisis in West Africa was quickly recognized as being driven as much by misinformation and rumors as by weaknesses in the health care system. Mohamed Komah interviews an Ebola survivor at the Donka Ebola treatment center in Conakry, Guinea. Photo by: Internews

International response agencies invested significant resources in rolling out the Social Mobilization and Community Engagement drive, a wide-scale intensive social behavior change communication campaign. The result was a massive and rather poorly coordinated blast of messaging shared on billboards, in print, on radio and TV, through health outreach workers and community organizations, via SMS and call-in hotlines.

A preliminary assessment done by Internews in November found more than 300 types of social mobilization and messaging systems in the three worst-affected countries: Liberia, Guinea and Sierra Leone. This chaotic information landscape consisted mainly of information “out,” with little opportunity for community dialogue....

AFP                                                                                April  23, 2015
Miami  - US regulators have issued an international recall for a 10-minute Ebola blood test made by a California-based company, saying it has not been proven to work and could put lives at risk.

"A recall has been issued for the LuSys Laboratories, Inc., Ebola Virus One-Step Test Kits because the FDA has not cleared or approved the kits for use or sale," said the Food and Drug Administration in a statement emailed to reporters on Thursday.

"The results obtained from these test kits have not demonstrated to be accurate and should not be used as in vitro diagnostic tests for Ebola infection."

Contacted by AFP, a company representative in San Diego said early trials have shown the test to be 86 percent accurate. The problem with the FDA came down to a labeling error, he said. The equipment had not been properly labeled "for research purposes only."

Read complete story.
http://news.yahoo.com/us-regulators-recall-10-minute-ebola-test-193530081.html;_ylt=AwrC1CmnSjlVNDsAZTDQtDMD;_ylu=X3oDMTByaWg0YW05BGNvbG8DYmYxBHBvcwM4BHZ0aWQDBHNlYwNzcg--

AFP 

(Scroll down for complete WHO report                                                                                         April 22, 2015

Geneva - More than 26,000 people have been infected with Ebola since the outbreak began and more than 10,800 have died, the World Health Organization said Wednesday.

The UN health body also warned that the decline in confirmed cases appeared to have stagnated, urging increased efforts to stop transmission of the deadly virus.

In all, 26,079 people have contracted the disease over the past 16 months, and 10,823 of them have died, almost all of them in Guinea, Liberia and Sierra Leone....

In the week leading to April 19, 33 new confirmed cases were reported, with 21 in Guinea, 12 in Sierra Leone and none in Liberia.

That compares to 37 new confirmed cases the week before, and 30 the week before that....

REUTERS by Aharon Begley                                                                    Aug. 22, 2015
NEW YORK --An experimental Ebola drug from Tekmira Pharmaceuticals Corp cured all three monkeys intentionally infected with the virus, scientists reported on Wednesday, the first such success against the strain of Ebola in West Africa's 2014-2015 outbreak.

Although other experimental treatments appeared to help Ebola patients last year, especially in the United States, those one-time uses cannot prove efficacy against the "Makona" strain, since patients' recovery might be due to other causes. Similarly, drugs, including Mapp Biopharmaceutical's ZMapp, cured monkeys in lab experiments, but in a strain of Ebola different from that responsible for the current outbreak, the worst ever recorded.

"We can't say for certain that an experimental drug that works against one strain will work in another, even if they're almost identical genetically," said Thomas Geisbert of the University of Texas Medical Branch, senior author of the study published in the journal Nature.